Cover Image

Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome

INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is used as an option treatment for pain relief among osteoarthritis patients. Tualang Honey Formulation (THF) (Patent no. MY179303-A) is currently being st...

Full description

Saved in:
Bibliographic Details
Main Authors: Abd Rahim, Nour El Huda, Zulkifly, Ahmad Hafiz, Mohd Jan, Nurul Hafiza, Ibrahim, Mohd Zulfadzli, Mohamad Amri, Nur Fathonah, Hassan, Habibah, Rajab, Nor Fadilah
Format: Article
Language:English
Published: Malaysian Orthopaedic Association (MOA) 2024
Subjects:
R Medicine (General)
RD Surgery
RD701 Orthopedics
Online Access:http://irep.iium.edu.my/116543/7/116543_Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis%20treatment.pdf
http://irep.iium.edu.my/116543/
https://www.morthoj.org/supplements/moa-2024/index.php
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.iium.irep.116543
record_format dspace
spelling my.iium.irep.1165432024-12-10T07:20:55Z http://irep.iium.edu.my/116543/ Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome Abd Rahim, Nour El Huda Zulkifly, Ahmad Hafiz Mohd Jan, Nurul Hafiza Ibrahim, Mohd Zulfadzli Mohamad Amri, Nur Fathonah Hassan, Habibah Rajab, Nor Fadilah R Medicine (General) RD Surgery RD701 Orthopedics INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is used as an option treatment for pain relief among osteoarthritis patients. Tualang Honey Formulation (THF) (Patent no. MY179303-A) is currently being studied as a viscosupplement option for OA treatment. This study aimed to investigate the cell mutagenic effect after exposure to THF towards biocompatibility profile. MATERIALS & METHODS: The bacterial tester strains (TA98, TA100, TA1535, TA1537 and WP2) were used to evaluate the mutagenicity of different concentrations of THF in the presence and absence of metabolic enzymes. The negative control was 0.9% NaCl. The positive controls were 4-nitro-o-phenylenediamine and 2-aminoanthracene. A total of 0.1ml of each concentration of THF was mixed with 0.5ml of buffer/S9 mix, followed by the addition of 0.1ml of each tester strain suspension. The mixture was then shaken in a water bath for 20-30 minutes at 37°C. The samples then were incubated at 37°C for 48 hours. The revertant colonies then were counted. RESULTS AND DISCUSSIONS: Figure 1 shows the number of colonies grown on the plates (revertant bacterial colonies counts) in all strains. The number of revertant colonies treated with the THF did not exceed twice the number of the negative control either in the presence or absence of metabolic activation. The negative and positive controls used in this study responded as expected. The outcome of this study showed that THF did not demonstrate a mutagenic effect on all bacterial strains, which indicated that THF could be used safely as a viscosuppplement in OA treatment. CONCLUSION: Based on the findings of this study, THF is a non-mutagenic and biocompatible. This outcome shows that THF is a potential viscosupplement for OA treatment in future. Malaysian Orthopaedic Association (MOA) 2024-07 Article PeerReviewed application/pdf en http://irep.iium.edu.my/116543/7/116543_Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis%20treatment.pdf Abd Rahim, Nour El Huda and Zulkifly, Ahmad Hafiz and Mohd Jan, Nurul Hafiza and Ibrahim, Mohd Zulfadzli and Mohamad Amri, Nur Fathonah and Hassan, Habibah and Rajab, Nor Fadilah (2024) Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome. Malaysian Orthopaedic Journal, 17 (Suppl. A). p. 1. ISSN 1985-2533 E-ISSN 2232-111X https://www.morthoj.org/supplements/moa-2024/index.php
institution Universiti Islam Antarabangsa Malaysia
building IIUM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider International Islamic University Malaysia
content_source IIUM Repository (IREP)
url_provider http://irep.iium.edu.my/
language English
topic R Medicine (General)
RD Surgery
RD701 Orthopedics
spellingShingle R Medicine (General)
RD Surgery
RD701 Orthopedics
Abd Rahim, Nour El Huda
Zulkifly, Ahmad Hafiz
Mohd Jan, Nurul Hafiza
Ibrahim, Mohd Zulfadzli
Mohamad Amri, Nur Fathonah
Hassan, Habibah
Rajab, Nor Fadilah
Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
description INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is used as an option treatment for pain relief among osteoarthritis patients. Tualang Honey Formulation (THF) (Patent no. MY179303-A) is currently being studied as a viscosupplement option for OA treatment. This study aimed to investigate the cell mutagenic effect after exposure to THF towards biocompatibility profile. MATERIALS & METHODS: The bacterial tester strains (TA98, TA100, TA1535, TA1537 and WP2) were used to evaluate the mutagenicity of different concentrations of THF in the presence and absence of metabolic enzymes. The negative control was 0.9% NaCl. The positive controls were 4-nitro-o-phenylenediamine and 2-aminoanthracene. A total of 0.1ml of each concentration of THF was mixed with 0.5ml of buffer/S9 mix, followed by the addition of 0.1ml of each tester strain suspension. The mixture was then shaken in a water bath for 20-30 minutes at 37°C. The samples then were incubated at 37°C for 48 hours. The revertant colonies then were counted. RESULTS AND DISCUSSIONS: Figure 1 shows the number of colonies grown on the plates (revertant bacterial colonies counts) in all strains. The number of revertant colonies treated with the THF did not exceed twice the number of the negative control either in the presence or absence of metabolic activation. The negative and positive controls used in this study responded as expected. The outcome of this study showed that THF did not demonstrate a mutagenic effect on all bacterial strains, which indicated that THF could be used safely as a viscosuppplement in OA treatment. CONCLUSION: Based on the findings of this study, THF is a non-mutagenic and biocompatible. This outcome shows that THF is a potential viscosupplement for OA treatment in future.
format Article
author Abd Rahim, Nour El Huda
Zulkifly, Ahmad Hafiz
Mohd Jan, Nurul Hafiza
Ibrahim, Mohd Zulfadzli
Mohamad Amri, Nur Fathonah
Hassan, Habibah
Rajab, Nor Fadilah
author_facet Abd Rahim, Nour El Huda
Zulkifly, Ahmad Hafiz
Mohd Jan, Nurul Hafiza
Ibrahim, Mohd Zulfadzli
Mohamad Amri, Nur Fathonah
Hassan, Habibah
Rajab, Nor Fadilah
author_sort Abd Rahim, Nour El Huda
title Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
title_short Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
title_full Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
title_fullStr Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
title_full_unstemmed Tualang Honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
title_sort tualang honey formulation as potential osteoarthritis treatment: in-vitro genotoxicity outcome
publisher Malaysian Orthopaedic Association (MOA)
publishDate 2024
url http://irep.iium.edu.my/116543/7/116543_Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis%20treatment.pdf
http://irep.iium.edu.my/116543/
https://www.morthoj.org/supplements/moa-2024/index.php
_version_ 1818833720627429376
score 13.235796

Similar Items